Catalyst
Slingshot members are tracking this event:
FibroGen (FGEN) 2/3 for MDS-associated anemia is in line to begin in third quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FGEN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2017
Occurred Source:
http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2309410
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Mds-associated Anemia, Phase 2/3 Study
